Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 7/20 | 0.64 |
| ▸ | AVPR1A | P37288 | 18/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2478194 | 1.00 | AVPR2 (0.64) | AVPR2AVPR1AKCNH2 | |
| SCHEMBL2474290 | 0.91 | AVPR1A (0.60) | AVPR2AVPR1AKCNH2 | |
| SCHEMBL3332026 | 0.91 | AVPR1A (0.60) | AVPR2AVPR1AKCNH2 | |
| SCHEMBL3331550 | 0.89 | AVPR1A (0.76) | AVPR2AVPR1AKCNH2 | |
| SCHEMBL3331544 | 0.89 | AVPR1A (0.76) | AVPR2AVPR1AKCNH2 | |
| SCHEMBL2472063 | 0.84 | AVPR1A (0.60) | AVPR2AVPR1AKCNH2 | |
| SCHEMBL3333451 | 0.84 | AVPR1A (0.60) | AVPR2AVPR1AKCNH2 | |
| SCHEMBL3333396 | 0.83 | AVPR1A (0.61) | AVPR2AVPR1AKCNH2 | |
| SCHEMBL2475010 | 0.83 | AVPR1A (0.61) | AVPR2AVPR1AKCNH2 | |
| SCHEMBL2533386 | 0.83 | AVPR1A (0.68) | AVPR2AVPR1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3035939-B1 | V1A ANTAGONISTS TO TREAT PHASE SHIFT SLEEP DISORDERS | HOFFMANN LA ROCHE (CH) | 2020-03-25 | — | — | EP | claimed |
| US-10265327-B2 | V1A antagonists to treat phase shift sleep disorders | HOFFMANN-LA ROCHE INC. (US) | 2019-04-23 | — | — | US | claimed |
| US-20180064727-A1 | V1A ANTAGONISTS TO TREAT PHASE SHIFT SLEEP DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2018-03-08 | — | — | US | claimed |
| EP-2370441-B1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-09-11 | — | — | EP | claimed |
| US-8461152-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-20120225865-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | SCHNIDER PATRICK (CH) | 2012-09-06 | — | — | US | claimed |
| US-8227458-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-20100137286-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | HOFFMANN-LA ROCHE, INC. | 2010-06-03 | — | — | US | claimed |
| US-10265327-B2 | V1A antagonists to treat phase shift sleep disorders | HOFFMANN-LA ROCHE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180064727-A1 | V1A ANTAGONISTS TO TREAT PHASE SHIFT SLEEP DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2018-03-08 | — | — | US | disclosed |
| EP-2370441-B1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8461152-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120225865-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | SCHNIDER PATRICK (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8227458-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100137286-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | HOFFMANN-LA ROCHE, INC. | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265327-B2 | V1A antagonists to treat phase shift sleep disorders | AVPR1A, AVPR1B, AVPR2 | AVPR2 3/4885AVPR1A 1/4885KCNH2 678/4885 |
| US-20180064727-A1 | V1A ANTAGONISTS TO TREAT PHASE SHIFT SLEEP DISORDERS | AVPR1A, AVPR1B, AVPR2 | AVPR2 3/4885AVPR1A 1/4885KCNH2 678/4885 |
| US-20120225865-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, AVPR2 | AVPR2 3/4885AVPR1A 1/4885KCNH2 490/4885 |
| US-20100137286-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, AVPR2 | AVPR2 3/4885AVPR1A 1/4885KCNH2 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.